DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the Nonalcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Nonalcoholic Steatohepatitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Nonalcoholic Steatohepatitis Pipeline Outlook
Key Takeaways from the Nonalcoholic Steatohepatitis Pipeline Report
- July 2024:- Boston Pharmaceuticals- A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension. This is a randomized, blinded, placebo-controlled study of BOS-580 in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
- DelveInsight’s Nonalcoholic Steatohepatitis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Nonalcoholic Steatohepatitis treatment.
- The leading Nonalcoholic Steatohepatitis Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
- Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.
Stay ahead with the most recent pipeline outlook for Nonalcoholic Steatohepatitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Nonalcoholic Steatohepatitis Treatment Drugs
Nonalcoholic Steatohepatitis Emerging Drugs Profile
- Lanifibranor: Inventiva Pharma
Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.
- MSDC-0602K: Cirius Therapeutics
MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.
- TERN-501: Terns Pharmaceuticals
TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.
- HTD 1801: HighTide Biopharma
The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
Explore groundbreaking therapies and clinical trials in the Nonalcoholic Steatohepatitis Pipeline. Access DelveInsight’s detailed report now! @ New Nonalcoholic Steatohepatitis Drugs
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Nonalcoholic Steatohepatitis Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Nonalcoholic Steatohepatitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Nonalcoholic Steatohepatitis Market Drivers and Barriers
Scope of the Nonalcoholic Steatohepatitis Pipeline Report
- Coverage- Global
- Nonalcoholic Steatohepatitis Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
- Nonalcoholic Steatohepatitis Therapies- AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.
- Nonalcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Nonalcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Nonalcoholic Steatohepatitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Nonalcoholic Steatohepatitis Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Nonalcoholic Steatohepatitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Lanifibranor: Inventiva Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TERN-501: Terns Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- LY3849891: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Nonalcoholic Steatohepatitis Key Companies
- Nonalcoholic Steatohepatitis Key Products
- Nonalcoholic Steatohepatitis- Unmet Needs
- Nonalcoholic Steatohepatitis- Market Drivers and Barriers
- Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
- Nonalcoholic Steatohepatitis Analyst Views
- Nonalcoholic Steatohepatitis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/